Abstract:Purpose: To compare serum levels of chemerin in type 2 diabetes mellitus (T2DM) with or without retinopathy, and to investigate the relationship between serum chemerin levels and diabetes retinopathy. Materials and methods: A total of 60 T2DM patients and 20 healthy subjects (control group) were enrolled in this study. Of the T2DM patients, 15 had proliferative diabetic retinopathy (PDR group), 20 had non-proliferative retinopathy (NPDR group) and 25 had no retinopathy (T2DM group). Their serum samples were collected for testing the levels of chemerin, vascular endothelial growth factor (VEGF), C-reactive protein (CRP) and so on. The values were analyzed to compare the differences among the groups. Simple linear regression analysis and multiple stepwise linear regression analysis were used to determine the correlations between variables and chemerin. Trend chi-square was used to determine the correlations between chemerin and the severity of diabetic retinopathy (DR). Results: Chemerin levels in group PDR, NPDR and no DR were 147.5635.98g/l, 128.09 +/- 16.33g/l and 113.19 +/- 19.89g/l, with the significant difference across the three groups (p<0.05). But there was no difference between control group (109.55 +/- 20.98g/l) and T2DM group. Simple linear regression show that serum chemerin was correlated with duration of diabetes, body mass index (BMI), serum triglycerides, total-cholesterol, CRP and VEGF, and not correlated with age, systolic and diastolic blood pressure in T2DM patients. Stepwise regression analysis showed that BMI, CRP and VEGF were significantly associated with serum chemerin (p=0.006, p=0.011 and p=0.036, respectively). In addition, the more severity of DR as the chemerin levels increased ((2)=16.07, p<0.001). Conclusions: Serum levels of chemerin were significantly increased in the NPDR and PDR group. Elevated serum level of chemerin and its positive correlation with BMI, CRP and VEGF suggested that chemerin was associated with obesity, inflammation and neovascularization and might be involved in the development of DR.

Relationship Between Serum MMP-9 and TIMP-1 in the Patients with Diabetic Retinopathy

Relationship Between Matrix Metalloproteinase-9 and Tissue Metalloproteinase Inhibitor-1 and Carotid Atheromatous Plaque Stability

Correlation of MMP-2, TIMP-1, β2-MG and hs-CRP with the progression of retinopathy in patients with type 2 diabetes

Correlation of MMP-9, GA, HbA1c, and Adipokines Levels with DR

Measure serum metalloproteinase matrix-9 and tissue inhibitor of metalloproteinase-1 in the patients with type 2 diabetic macroangiopathy

Value of Matrix Metalloproteinase - 9 and Ischemia - Modified Albumin for Diagnosis of Coronary Heart Disease

Plasma matrix metalloproteinases and tissue inhibitors of metalloproteinases explored in relation to the severity and progression of diabetic retinopathy in patients with type 1 diabetes: baseline and prospective analyses

Basic regulatory effects and clinical value of metalloproteinase-14 and extracellular matrix metalloproteinase inducer in diabetic retinopathy

Association of diabetic retinopathy with serum periostin and vascular endothelial growth factor

Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy

Influence of serum CTRP3, CTRP9 on patients with diabetic retinopathy and its relationship study

Changes in Serum Metalloproteinase Matrix-9 Levels in Patients with Concomitant Coronary Heart Disease and Diabetes Mellitus

[Expression of Matrix Metalloproteinase-2 And-9 in Kidney of Diabetic Rats].

Changes of Insulin - Like Growth Factor in Serum in Patients with Diabetic Retinopathy

Matrix Metalloproteinases in Diabetic Retinopathy: Potential Role of MMP-9

Increased Levels of IL-6, Sil-6R, and Sgp130 in the Aqueous Humor and Serum of Patients with Diabetic Retinopathy.

Increased Serum Chemerin Levels in Diabetic Retinopathy of Type 2 Diabetic Patients.

Decreased expression of Glucagon-like peptide-1 receptor and Sodium-glucose co-transporter 2 in patients with proliferative diabetic retinopathy

Downregulation of SIRT6 and NMNAT2 is Associated with Proliferative Diabetic Retinopathy.

Association of matrix metalloproteinase and their tissue inhibitors gene polymorphisms with progression of angiographic coronary plaque in type 2 diabetic patients

Association of MMP-9 with Vascular Pathogenesis in Diabetic Patients